论文部分内容阅读
据美国儿科学会宣称,美国将引进日本在过去10年中广泛使用的百日咳无细胞菌苗作加强接种以预防儿童百日咳。该学会说,日本和瑞典的研究表明,对15～18月龄婴儿和4～6岁儿童接种这种菌苗安全有效。还说,该菌苗引起的不良反应低于美国使用的百日咳全细胞菌苗。近年来,对百日咳全细胞菌苗的接种是有争论的,一些家长由于担心对孩子接种全细胞菌苗会引起脑损伤而拒绝接种。美国食品与药物管理局正评论这种百日咳无细胞菌苗是否会批准对15月龄以上儿童作加强接种。该学会说,
According to the American Academy of Pediatrics, the United States will introduce Japan’s aseptic acellular bacterin in Japan over the past 10 years to boost vaccination against whooping cough in children. The institute said studies in Japan and Sweden have shown that it is safe and effective to vaccinate infants aged 15 to 18 months and children aged 4 to 6 years. Added that the adverse reactions caused by the vaccine were lower than the B. pertussis whole-cell vaccine used in the United States. In recent years, vaccination of B. pertussis whole-cell vaccine has been controversial, with some parents refusing to vaccinate their children for fear of causing brain damage when vaccinated with whole-cell vaccines. The U.S. Food and Drug Administration is commenting on whether such a whooping cough cell-free vaccine will be approved for intensified vaccination of children over the age of 15 months. The society said,